The pharmacoeconomics of hormone replacement therapy

PharmacoEconomics

Volumn 16, Issue 1, 1999, Pages 9-16

  Torgerson, David J ^a   Reid, David M ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; ELLESTE DUET; ELLESTE SOLO; ESTRACOMBI; ESTRADIOL; ESTRADIOL VALERATE PLUS NORGESTREL; ESTROGEN RECEPTOR; HORMONIN; PREMPAK; UNCLASSIFIED DRUG;

ADULT; BONE DENSITY; BONE MASS; BREAST CANCER; CANCER INCIDENCE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG FORMULATION; FEMALE; FRACTURE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SYMPTOMATOLOGY;

COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE;

EID: 0032808191     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916010-00002     Document Type: Review

References (31)

1. 1. Barrett-Connor H. Hormone replacement therapy. BMJ 1998; 317: 457-61
2. 2. Torgerson DJ, Reid DM. The economics of osteoporosis and its prevention. PharmacoEconomics 1997; 11 (2): 126-38
3. 3. Torgerson DJ, Gosden T, Reid DM. The economics of osteoporosis prevention. Trends Endocrinol Metab 1997; 8: 236-9
4. 4. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37
5. 5. Weinstein MC. Estrogen use in postmenopausal women costs, risks, benefits. N Engl J Med 1980; 303: 308-16
6. 6. Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993; 307: 836-40
7. 7. Eddy DM, Johnston CC, Cummings SR, et al. Osteoporosis: cost-effectiveness analysis and review of the evidence for prevention, diagnosis and treatment. Osteoporos Int 1998; 4 Suppl. 2: ii-vii
8. 8. Dolan P, Torgerson DJ, Kumar TK. The effect of a Colle's fracture on quality of life. Osteoporos Int 1999; 9: 196-9
9. 9. Zethraeus N, Stromberg L, Jonsson B, et al. The cost of a hip fracture: estimates for 1709 patients in Sweden. Acta Orthop Scand 1997; 68: 13-7
10. 10. Medical Research Council. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ 1996; 312: 473-8
11. 11. Torgerson DJ, Donaldson C, Russell IT, et al. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynaecol Reprod Biol 1995; 59: 57-60
12. 12. Torgerson DJ, Thomas RE, Campbell MK, et al. Randomised trial of osteoporosis screening: HRT uptake and quality of life results. Arch Intern Med 1997; 157: 2121-5
13. 13. Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336: 265-9
14. 14. Place VA, Powers M, Darley PE, et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985; 152: 1092-9
15. 15. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9
16. 16. Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and Vit D in prevention of non vertebral fractures in postmenopausal women: a 5 year randomized trial. Maturitas 1998; 31: 45-54
17. 17. Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen and progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13
18. 18. Royal College of Physicians. Clinical guidelines for the prevention and treatment of osteoporosis. London: RCP, 1998
19. 19. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9-16
20. 20. Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and the risk of hip fracture: population based case-control. BMJ 1998; 316: 1858-63
21. 21. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 without breast cancer. Lancet 1997; 350: 1047-59
22. 22. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149-53
23. 23. Tosteson ANA, Weinstein M. Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol 1991; 5: 943-59
24. 24. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-59
25. 25. Torgerson DJ, Reid DM. Estimating the cost effectiveness of screening tests. QJM 1997; 90 (10): 649-52
26. 26. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women. JAMA 1996; 276 (17): 1404-8
27. 27. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997; 336: 611-7
28. 28. Johansen A, Evans RJ, Stone MD, et al. Fracture incidence in England and Wales: a study based on the population of Cardiff. Injury 1997; 28: 655-60
29. 29. Torgerson DJ, Campbell MK, Thomas RE, et al. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res 1996; 11 (2): 293-7
30. 30. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7
31. 31. Ettinger B, Black D, Cummings S, et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. Osteoporos Int 1998; 9 Suppl. 3: 11